Patents Examined by Einar Stole
  • Patent number: 6274139
    Abstract: Topoisomerase I polypeptides and DNA and RNA encoding such Topoisomerase I polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such Topoisomerase I for the treatment of infection, particularly bacterial infections. Antagonists against such Topoisomerase I and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of Topoisomerase I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding Staphylococcal Topoisomerase I and for detecting the polypeptide in a host.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: August 14, 2001
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Michael N. Gwynn, Howard Kallendar, Leslie M. Palmer
  • Patent number: 6251648
    Abstract: A human DNase polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating bronchopulmonary conditions. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: June 26, 2001
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig Rosen, Steven M. Ruben, Mark D. Adams
  • Patent number: 6251867
    Abstract: Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: June 26, 2001
    Assignee: Abbott Laboratories
    Inventor: Donald J. Davidson
  • Patent number: 6238905
    Abstract: The present invention relates to gene and amino acid sequences encoding DNA polymerase III holoenzyme subunits and structural genes from thermophilic organisms. In particular, the present invention provides DNA polymerase III holoenzyme subunits of T. thermophilus. The present invention also provides antibodies and other reagents useful to identify DNA polymerase III molecules.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: May 29, 2001
    Assignee: University Technology Corporation
    Inventors: Charles S. McHenry, Mark Seville, Millard G. Cull
  • Patent number: 6235519
    Abstract: The present invention relates to an isolated nucleic acid molecule which encodes one or more of the enzymes which catalyze one or more steps in the desulfurization of thiophene, or a homologue or active fragment thereof. The invention also includes a recombinant microorganism containing one or more such heterologous nucleic acid molecules. The invention also provides a method for desulfurizing a fossil fuel containing thiophene and/or one or more substituted thiophenes. The method comprises contacting the fossil fuel with an organism containing a recombinant nucleic acid molecule which encodes an enzyme which catalyzes the desulfurization of thiophene.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: May 22, 2001
    Assignee: Energy Biosystems Corporation
    Inventors: Yongzhao Wang, John D. Childs, Charles H. Squires
  • Patent number: 6225075
    Abstract: The invention provides an isolated and purified nucleic acid molecule encoding a Candida albicans sterol methyltransferase (ERG6). Also provided is a C. albicans strain or isolate that has reduced levels of sterol methyltransferase as a result of the disruption of at least one sterol methyltransferase gene. Preferred isolates are more susceptible to a number of sterol synthesis and metabolic inhibitors relative to wild type isolates. Further provided are methods to identify sterol methyltransferase inhibitors and methods to screen for antifungals or metabolic inhibitors which are not normally permeable to the fungal cell.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: May 1, 2001
    Assignee: Advanced Research and Technology Institute, Inc.
    Inventor: Martin Bard
  • Patent number: 6221636
    Abstract: A recombinant DNA autonomously replicable in cells of coryneform bacteria, comprising a DNA sequence coding for an aspartokinase in which feedback inhibition by L-lysine and L-threonine is substantially desensitized, and a DNA sequence coding for a diaminopimelate decarboxylase; a coryneform bacterium harboring an aspartokinase in which feedback inhibition by L-lysine and L-threonine is substantially desensitized, and comprising an enhanced DNA sequence coding for a diaminopimelate decarboxylase; and a method for producing L-lysine comprising the steps of cultivating the coryneform bacterium in an appropriate medium to allow L-lysine to be produced and accumulated in a culture of the bacterium, and collecting L-lysine from the culture.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: April 24, 2001
    Assignee: Ajinomoto Co., Inc.
    Inventors: Atsushi Hayakawa, Masakazu Sugimoto, Yasuhiko Yoshihara, Tsuyoshi Nakamatsu
  • Patent number: 6214588
    Abstract: Eukaryotic RNA polymerase II holoenzymes that contain RNA polymerase II and one or more regulatory proteins are described. These holoenzymes selectively initiate transcription in vitro when supplemented with general transcription factors. The regulatory proteins act positively and negatively to regulate transcription initiation, at least in part, via functional interactions with RNA polymerase II.
    Type: Grant
    Filed: January 26, 1996
    Date of Patent: April 10, 2001
    Assignee: Whitehead Institute Biomedical Research
    Inventors: Richard A. Young, Anthony J. Koleske, Craig M. Thompson, David M. Chao
  • Patent number: 6207430
    Abstract: The present invention relates to polypeptides having laccase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: March 27, 2001
    Assignee: Novo Nordisk of Biotech, Inc.
    Inventors: Debbie Sue Yaver, Kimberley M. Brown, Sakari Kauppinen, Torben Halkier
  • Patent number: 6200794
    Abstract: The present invention relates to fatty acid 13-hydroperoxide lyase protein from guava (Psidium guajava) and the gene encoding the protein. Expression systems for recombinant guava 13-hydroperoxide lyase and methods of using recombinant guava 13-hydroperoxide lyase for the production of green notes are provided.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: March 13, 2001
    Assignees: Fimenrich SA, University of Zurich, Vanderbilt University
    Inventors: Ian Michael Whitehead, Alan John Slusarenko, Urs Wäspi, Duncan James Horatio Gaskin, Alan Richard Brash, Nathalie Tijet
  • Patent number: 6180401
    Abstract: A method of producing a polypeptide in fed batch cell culture is provided which involves an initial cell growth phase and a distinct production phase. In the initial growth stage, animal cells having nucleic acid encoding the polypeptide are cultured at a starting osmolality of about 280-330 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0.01 and 1 g/L. This is followed by a production phase, where the cultured animal cells of the growth phase are inoculated at a cell seed density of at least 1.0×106 cells/mL and the cells are cultured at a starting osmolarity of about 400-600 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0.01 and 1 g/L. Preferably, the glutamine concentration in the cell culture medium is simultaneously controlled in order to curtail production of lactic acid and ammonia which result from unnecessarily high glutamine concentrations.
    Type: Grant
    Filed: May 4, 1998
    Date of Patent: January 30, 2001
    Assignee: Genentech, Inc.
    Inventors: Mary Chen, Lawrence W. Forman
  • Patent number: 6180334
    Abstract: The invention relates to novel recombinant substrates for aggrecanase. In one embodiment, this substrate comprises the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, the interglobular domain of human aggrecan, the hinge region of human IgG1, the CH2 region of human IgG1 and the CH3 region of human IgG1. DNA sequences encoding the recombinant substrate are also provided, as are vectors and host cells containing said DNA. Various methods are provided for: monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and cloning the aggrecanase cDNA, screening for aggrecanase inhibitors; and for monitoring the onset or progression of osteoarthritis. A diagnostic aid containing the recombinant substrate is also provided.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: January 30, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eckart Bartnik, Bernd Eidenmueller, Frank Buettner, Bruce Caterson, Clare Hughes
  • Patent number: 6177257
    Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: January 23, 2001
    Assignee: SmithKline Beechman
    Inventors: Colin Houston Macphee, David Graham Tew, Christopher Donald Southan, Deirdre Mary Bernadette Hickey, Israel Simon Gloger, Geoffrey Mark Prouse Lawrence, Simon Quentyn John Rice
  • Patent number: 6171843
    Abstract: The invention provides human peptidyl-prolyl isomerases (HPPIP) and polynucleotides which identify and encode HPPIP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HPPIP.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: January 9, 2001
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal, Neil C. Corley, Chandra Patterson, Mariah R. Baughn
  • Patent number: 6165765
    Abstract: The invention relates to genetical modification of DNA polymerase to reduce its innate selective sequence-related discrimination against incorporation of fluorescent dye-labeled ddCTP and ddATP in the enzymatic reaction for preparation of samples for automated florescent dye-labeled terminator DNA sequencing. The modified DNA polymerases are more resistant to heat inactivation and are more effective in dideoxynucleotide incorporation than current DNA polymerases.
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: December 26, 2000
    Assignee: Shanghai Institute of Biochemistry, Chinese Academy of Sciences
    Inventors: GuoFan Hong, Wei-hua Huang
  • Patent number: 6156310
    Abstract: Topoisomerase III polypeptides and DNA and RNA encoding such Topoisomerase III polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such Topoisomerase III for the treatment of infection, particularly bacterial infections. Antagonists against such Topoisomerase III and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of Topoisomerase III nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding Staphylococcal Topoisomerase III and for detecting the polypeptide in a host.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: December 5, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael N. Gwynn, Howard Kallendar, Leslie M. Palmer
  • Patent number: 6146862
    Abstract: The present invention provides a gene derived from a thermophilic Bacillus, comprising the nucleotide sequence of SEQ ID No.2 and encoding a thermostable diaphorase comprising the amino acid sequence of SEQ ID No.1, a recombinant vector possessing the gene, a transformant with the recombinant vector and a process for producing the thermostable diaphorase by using the transformant.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: November 14, 2000
    Assignee: Unitaka Ltd.
    Inventors: Shido Kawase, Hitoshi Kondo, Munehiko Dombou
  • Patent number: 6136964
    Abstract: There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
    Type: Grant
    Filed: March 19, 1996
    Date of Patent: October 24, 2000
    Assignee: Cell Therapeutics, Inc.
    Inventors: David W. Leung, James W. West, Christopher K. Tompkins
  • Patent number: 6133016
    Abstract: The invention relates to a novel microorganism, designated Sphingomonas sp. strain AD109, which is capable of selectively desulfurizing dibenzothiophene. The invention also includes isolated proteins and nucleic acid sequences obtained from this microorganism. In another embodiment, the invention provides a method of using this microorganism or enzyme preparations derived therefrom in the biocatalytic desulfurization of a fossil fuel containing organic sulfur compounds.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: October 17, 2000
    Assignee: Energy BioSystems Corporation
    Inventors: Aldis Darzins, Gregory T. Mrachko
  • Patent number: 6120771
    Abstract: The invention provides MurE polypeptides and DNA (RNA) encoding MurE polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing MurE polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: September 19, 2000
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham plc
    Inventor: Nicola Gail Wallis